Henry Schein, Inc. is an American distributor of health care products and services, with operations in 33 countries and territories. It is the world’s largest provider of health care solutions to office-based dental and medical practitioners.
Baird's upgrade signals growing confidence in the dental market recovery, which is important for healthcare investors tracking post-pandemic trends. The improved patient volumes and pricing trends indicate broader economic health in elective healthcare services. This upgrade could influence other analysts' ratings and investor sentiment toward the dental supply sector.
Context & Background
Henry Schein is a major dental products distributor trading on NASDAQ as HSIC
The stock was upgraded from Neutral to Outperform with price target raised from $78 to $100
Dental market faced patient volume declines of 2-3% year-over-year in late 2025
What Happens Next
Investors will watch Henry Schein's Q4 2025 earnings for confirmation of the projected 5% consumables growth. The company's new CEO Frederick M. Lowery will take leadership in March 2026, potentially bringing strategic changes. Continued monitoring of patient volume trends through mid-2026 will validate the recovery thesis.
Frequently Asked Questions
What was Henry Schein's stock rating before the upgrade?
Baird upgraded Henry Schein from Neutral to Outperform.
What is the new price target set by Baird?
Baird raised its price target to $100 from $78.
What evidence supports the dental market recovery?
Survey data shows patient volumes improved from declines of 2-3% to flat/slight growth, and consumables pricing increased year-over-year.
}
Original Source
try{ var _=i o; . if(!_||_&&typeof _==="object"&&_.expiry Gold prices extend gains on fresh Trump tariff jitters Can gold rise to new highs above $5,600 in 2026? Bitcoin slips after earlier gains amid tariff volatility Bull vs. bear argument on Friday’s Supreme Court tariff ruling (South Africa Philippines Nigeria) Baird upgrades Henry Schein stock rating on dental market recovery By Investing.com Analyst Ratings Published 02/23/2026, 02:49 AM Baird upgrades Henry Schein stock rating on dental market recovery 0 HSIC 3.61% Investing.com - Baird upgraded Henry Schein (NASDAQ:HSIC) to Outperform from Neutral on Monday and raised its price target to $100.00 from $78.00. The stock currently trades at $79.57, near its 52-week high of $82.80, reflecting growing investor confidence in the dental distributor’s prospects. The firm cited modest improvements in North American patient volumes to start 2026. Survey data suggests patient volumes improved roughly two percentage points back to flat to slight year-over-year growth versus patient volume declines closer to 2-3% year-over-year over much of the back-half of 2025. Baird said consumables pricing across the U.S. market is up a couple points on a year-over-year basis and improved one to two points versus the first half of 2025. The firm expects this to provide another point or two of growth tailwinds for Henry Schein’s fourth-quarter 2025 and first-half 2026 U.S. dental consumables growth. The firm believes these factors will help Henry Schein report stable to improved year-over-year growth for its U.S. dental consumables revenue in fourth-quarter 2025 versus third-quarter 2025. The company reported 3.3% year-over-year U.S. consumables growth in the third quarter of 2025. Baird said U.S. consumables growth for Henry Schein could reach 5% or higher in the fourth quarter. The firm expects modestly improving patient volumes and continued year-over-year incremental pricing tailwinds through at least first-half 2026 to potentiall...
